Meclofenoxate therapy in tardive dyskinesia: A preliminary report

Izumi, Kanji; Tominaga, Hidefumi; Koja, Takeshi; Nomoto, Masahiro; Shimizu, Takao; Sonoda, Hiroshi; Imamura, Kazuhide; Igata, Akihiro; Fukuda, Takeo

doi:10.1016/0006-3223(86)90142-3

Cited by 12 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Physostigmine, a centrally acting cholinesterase inhibitor, has been used to investigate the pharmacology of TD, with mixed results (Lieberman et al 1988 a , 1988 b ; Yagi et al 1989). An encouraging preliminary study using the cholinergic releasing agent meclofenoxate found improvement in 5 of 11 patients (Izumi et al 1986). Tacrine (or THA) is a recently released cholinesterase inhibitor primarily used for the treatment of Alzheimer’s disease.…”

Section: Suppressive Therapies For Tdmentioning

confidence: 99%

Treatment of Tardive Dyskinesia

Egan

Apud

Wyatt

1997

Schizophrenia Bulletin

136

View full text Add to dashboard Cite

Although the new generation of atypical antipsychotic agents could some day eliminate concerns about tardive dyskinesia (TD), this disorder remains a significant clinical problem for both patients and physicians. Fortunately, many, if not most, cases of TD are mild. For patients with mild to moderate TD, therapeutic efforts are primarily directed at minimizing neuroleptic exposure or, when possible, changing to atypical agents. Most cases of TD do not seem to progress, suggesting that the risk of remaining on typical neuroleptics is probably small. Patients with moderate to severe forms of TD present greater challenges. These patients frequently require medication to suppress their dyskinesias. A variety of suppressive agents have been tried with limited success. No treatment strategy has emerged that is clearly superior or even successful in most patients. Increasing doses of typical neuroleptics may be useful for short-term suppression; however, the long-term efficacy and risk of this strategy have not been studied carefully. Data on atypical neuroleptics are scant. Clozapine's short-term suppressive effects seem, at best, weak, but patients may improve with long-term treatment. Medications with relatively few side effects that may have suppressive efficacy for some patients include calcium channel blockers, adrenergic antagonists, and vitamin E. Gamma-amino-butyric acid agonists agents and dopamine depleters are frequently useful, but have troubling side effects of their own. A variety of other medications have been employed, but are not well studied. For patients with tardive dystonia, anticholinergic agents or botulinum toxin has been particularly effective. Efforts to understand the neurobiology of TD may shed light on this persistent clinical conundrum.

show abstract

Section: Suppressive Therapies For Tdmentioning

confidence: 99%

Treatment of Tardive Dyskinesia

Egan

Apud

Wyatt

1997

Schizophrenia Bulletin

136

View full text Add to dashboard Cite

show abstract

“…Parthenolide has potential therapeutic effects in luminal A breast cancer [ 63 ]. Meclofenoxate is effective in the treatment of neuroleptic-induced dyskinesia [ 64 ], as well as alcoholism and dementia [ 65 ]. Lomustine has shown favorable results in the treatment of glioblastoma [ 66 , 67 ].…”

Section: Discussionmentioning

confidence: 99%

Development of novel lysosome-related signatures and their potential target drugs based on bulk RNA-seq and scRNA-seq for diabetic foot ulcers

Tan,

Qu,

Wang

2024

Hum Genomics

View full text Add to dashboard Cite

Background Diabetic foot ulcers (DFU) is the most serious complication of diabetes mellitus, which has become a global health problem due to its high morbidity and disability rates and the poor efficacy of conventional treatments. Thus, it is urgent to identify novel molecular targets to improve the prognosis and reduce disability rate in DFU patients. Results In the present study, bulk RNA-seq and scRNA-seq associated with DFU were downloaded from the GEO database. We identified 1393 DFU-related DEGs by differential analysis and WGCNA analysis together, and GO/KEGG analysis showed that these genes were associated with lysosomal and immune/inflammatory responses. Immediately thereafter, we identified CLU, RABGEF1 and ENPEP as DLGs for DFU using three machine learning algorithms (Randomforest, SVM-RFE and LASSO) and validated their diagnostic performance in a validation cohort independent of this study. Subsequently, we constructed a novel artificial neural network model for molecular diagnosis of DFU based on DLGs, and the diagnostic performance in the training and validation cohorts was sound. In single-cell sequencing, the heterogeneous expression of DLGs also provided favorable evidence for them to be potential diagnostic targets. In addition, the results of immune infiltration analysis showed that the abundance of mainstream immune cells, including B/T cells, was down-regulated in DFUs and significantly correlated with the expression of DLGs. Finally, we found latamoxef, parthenolide, meclofenoxate, and lomustine to be promising anti-DFU drugs by targeting DLGs. Conclusions CLU, RABGEF1 and ENPEP can be used as novel lysosomal molecular signatures of DFU, and by targeting them, latamoxef, parthenolide, meclofenoxate and lomustine were identified as promising anti-DFU drugs. The present study provides new perspectives for the diagnosis and treatment of DFU and for improving the prognosis of DFU patients.

show abstract

“…In a double-blind study, meclofenoxate also increased mental alertne dation of new information into long-term memory in elderly people [57]. I ful therapeutic tool for potentiating depressed cholinergic neurons and trea tic-induced dyskinesias [58]. Meclofenoxate improves the status of qualit consciousness, has an antihypoxic effect, and is used to mitigate the overa speech, thinking, and mental activity caused by CNS intoxication and inj been tested for treating Alzheimer's disease and vascular dementia [59].…”

Section: Meclofenoxatementioning

confidence: 99%

“…Meclofenoxate is deemed to be safe and tolerable. Possible side effects are often caused by overdose, including dizziness, restlessness, nausea, and headache [58,60]. [51].…”

Section: Meclofenoxatementioning

confidence: 99%

Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs

Malík

Tlustos

2022

Nutrients

View full text Add to dashboard Cite

Nootropics, also known as “smart drugs” are a diverse group of medicinal substances whose action improves human thinking, learning, and memory, especially in cases where these functions are impaired. This review provides an up-to-date overview of the potential effectiveness and importance of nootropics. Based on their nature and their effects, this heterogeneous group of drugs has been divided into four subgroups: classical nootropic compounds, substances increasing brain metabolism, cholinergic, and plants and their extracts with nootropic effects. Each subgroup of nootropics contains several main representatives, and for each one, its uses, indications, experimental treatments, dosage, and possible side effects and contraindications are discussed. For the nootropic plant extracts, there is also a brief description of each plant representative, its occurrence, history, and chemical composition of the medicinal part. Lastly, specific recommendations regarding the use of nootropics by both ill and healthy individuals are summarized.

show abstract

Meclofenoxate therapy in tardive dyskinesia: A preliminary report

Cited by 12 publications

References 17 publications

Treatment of Tardive Dyskinesia

Treatment of Tardive Dyskinesia

Development of novel lysosome-related signatures and their potential target drugs based on bulk RNA-seq and scRNA-seq for diabetic foot ulcers

Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs

Contact Info

Product

Resources

About